Korro Bio appoints Dr. Kemi Olugemo as Chief Medical Officer

Korro Bio, Inc.

Dr. Olugemo joined as CMO effective May 13, 2024; prior role was VP of Global Clinical Development at Ultragenyx.
Previously Head of Clinical Development at Laronde (now Sail Bio) and Executive Director at Ionis Pharmaceuticals.
Over 10 years of neurology and rare disease clinical development experience, including global approvals.
M.D. from University of Maryland School of Medicine with fellowship in Neuroimmunology & Multiple Sclerosis.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.